Clinical trial

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

NCT01178411

Study summary

ClinicalTrials.gov

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Tivantinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Anti-Cancer Combination Therapy Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2010-08-31

PhasePHASE1 / PHASE2

Conditions

Advanced Solid Tumorsunresolved

Interventions

TivantinibDRUG

Anti-Cancer Combination TherapyDRUG

Sponsors & collaborators

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01178411 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.